The study design and the pharmacodynamic profile of IDegAsp probably had a strong impact on the results; specifically on the rate of overall confirmed hypoglycemia, insulin dose, FPG and prandial glucose control as well as on body weight in the IDegAsp group. Here, INS is linked to Hypoglycemia.